Blueprint Medicines Corporation (BPMC) saw a big move in the last trading session, as the company’s shares fell by nearly 8% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for BPMC, as the stock is now up over 14% in the past one-month time frame.
The biopharmaceutical company, which focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets, has seen a flat track record when it comes to current year estimate revisions, as there has been no revision on either side over the past few weeks. The consensus for earnings estimate hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.
BPMC currently holds a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Investors interested in the Medical — Biomed/Genetics industry may consider a better-ranked stock like Actelion Ltd. (ALIOF), carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BLUEPRINT MED (BPMC): Free Stock Analysis Report
ACTELION LTD (ALIOF): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research